{"paper_id": "1be11c6bdd6619485cf5b3e1e67e37ee5b5d430f", "metadata": {"title": "SUPPLEMENTARY INFORMATION Selection of antigenically advanced variants of seasonal influenza viruses", "authors": [{"first": "Chengjun", "middle": [], "last": "Li", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Masato", "middle": [], "last": "Hatta", "suffix": "", "affiliation": {}, "email": ""}, {"first": "David", "middle": ["F"], "last": "Burke", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jihui", "middle": [], "last": "Ping", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Ying", "middle": [], "last": "Zhang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Makoto", "middle": [], "last": "Ozawa", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Andrew", "middle": ["S"], "last": "Taft", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Subash", "middle": ["C"], "last": "Das", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Anthony", "middle": ["P"], "last": "Hanson", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jiasheng", "middle": [], "last": "Song", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Masaki", "middle": [], "last": "Imai", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Peter", "middle": ["R"], "last": "Wilker", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Tokiko", "middle": [], "last": "Watanabe", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Shinji", "middle": [], "last": "Watanabe", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Mutsumi", "middle": [], "last": "Ito", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Kiyoko", "middle": [], "last": "Iwatsuki-Horimoto", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Colin", "middle": ["A"], "last": "Russell", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Sarah", "middle": ["L"], "last": "James", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Eugene", "middle": [], "last": "Skepner", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Eileen", "middle": ["A"], "last": "Maher", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Gabriele", "middle": [], "last": "Neumann", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Alexander", "middle": ["I"], "last": "Klimov", "suffix": "", "affiliation": {}, "email": ""}, {"first": "\u2020", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Anne", "middle": [], "last": "Kelso", "suffix": "", "affiliation": {}, "email": ""}, {"first": "John", "middle": [], "last": "Mccauley", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Dayan", "middle": [], "last": "Wang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yuelong", "middle": [], "last": "Shu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Takato", "middle": [], "last": "Odagiri", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Masato", "middle": [], "last": "Tashiro", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Xiyan", "middle": [], "last": "Xu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "David", "middle": ["E"], "last": "Wentworth", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jacqueline", "middle": ["M"], "last": "Katz", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Nancy", "middle": ["J"], "last": "Cox", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Derek", "middle": ["J"], "last": "Smith", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yoshihiro", "middle": [], "last": "Kawaoka", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [], "body_text": [{"text": "an antigenic map based on data with nine additional ferret antisera (pink squares) raised against nine mutant viruses (purple circles). HI titres were determined for selected viruses (represented by orange, purple, blue and cyan circles) against these new antisera together with three antisera (red squares) shown in panel 3a that were used to generate the original antigenic map. The faint antisera squares in panel 3b represent the original sera that were not retested in this experiment. The map in 3b was generated by analyzing the HI of the viruses (depicted by orange, purple, blue and cyan circles) tested with the nine new (pink squares) plus three original (red squares) antisera, along with the original HI data used to make the map in 3a. In both panels, the remaining antigenic escape variants examined in this study are shown as small grey circles. No significant changes in the positions of viruses or antisera were seen between the two maps. Clone number (%) Total clones sequenced 24 Wild-type clones 2 (8%) Non-functional mutant clones b 6 (25%)", "cite_spans": [], "ref_spans": [], "section": ""}, {"text": "Functional mutant clones 1 amino acid change 5 (31%) 2 amino acid changes 6 (38%) 3 amino acid changes 3 (19%) 4 amino acid changes 1 (6%) 5 amino acid changes 1 (6%) Total number of clones with amino acid change(s) 16 (67%) a Random mutations were introduced by error-prone PCR into the globular head region (amino acid positions 54-253) of A/Norway/3858/2009 HA. Twenty-four cDNA clones were sequenced to evaluate the diversity of the library. b \"Non-functional\" clones acquired a stop codon or a nucleotide deletion so that functional HA protein should no longer be expressed. AAA  GGA  AAT  GCT  ATG  AAC  CTG  AAC  TAG*  GAT  TGC  CGA  TTT  GGA  AGA  ACA  GGG  AAA  AGT  GGT  TCC  ATC  AGG  TTC  TGT  TTT  AGG  TCC  TCC  TCC  CTA  TGT  GCT  GTA  GAC  AAA  CAC  TCG  AAT  TGT  CAT  CGT  TCC  TGA* c  AAA  TGA*  GAT  GGT  AGG  GTG  ATA  TCC  GGT  ATT  GAA  TTG  CCT  TTT  TTT  AAA  ATT  ATT  CGC  ACG  ATC  TCG  GCA  TCT  TCG  GGG  AGT  GTT  TGA*  TGT  GAC  TCA  TCG  GAT  TGT  GGT  TCA  TAA*  GAC  GCT  AGG  CAA  TTC  TTT  GCA  AGA  TAA*  TTC  GTT  TAC  GGG  CCC  TGG  GCG  GCG  AAG  GAC  TAA*  GAG  TTT  GTA  CGA  ACC  CTG  GGA  TTT  TGA*  ACG  GGT  CCA  AAA  AAC  AGC  GTA  CTA  TTT  GAC  CCT  ACT  GGC  TCC  TGG  TCG  AAA  AGA  GAG  TCG  AGC  AAA  GTG  TGC  GAA  AGG  CCA All large amino acids *The position of this antiserum in the antigenic map was not well-coordinated and the antiserum was excluded from the analysis. ", "cite_spans": [], "ref_spans": [{"start": 580, "end": 1278, "text": "AAA  GGA  AAT  GCT  ATG  AAC  CTG  AAC  TAG*  GAT  TGC  CGA  TTT  GGA  AGA  ACA  GGG  AAA  AGT  GGT  TCC  ATC  AGG  TTC  TGT  TTT  AGG  TCC  TCC  TCC  CTA  TGT  GCT  GTA  GAC  AAA  CAC  TCG  AAT  TGT  CAT  CGT  TCC  TGA* c  AAA  TGA*  GAT  GGT  AGG  GTG  ATA  TCC  GGT  ATT  GAA  TTG  CCT  TTT  TTT  AAA  ATT  ATT  CGC  ACG  ATC  TCG  GCA  TCT  TCG  GGG  AGT  GTT  TGA*  TGT  GAC  TCA  TCG  GAT  TGT  GGT  TCA  TAA*  GAC  GCT  AGG  CAA  TTC  TTT  GCA  AGA  TAA*  TTC  GTT  TAC  GGG  CCC  TGG  GCG  GCG  AAG  GAC  TAA*  GAG  TTT  GTA  CGA  ACC  CTG  GGA  TTT  TGA*  ACG  GGT  CCA  AAA  AAC  AGC  GTA  CTA  TTT  GAC  CCT  ACT  GGC  TCC  TGG  TCG  AAA  AGA  GAG  TCG  AGC  AAA  GTG  TGC  GAA  AGG  CCA", "ref_id": null}], "section": "K K S A A Q S G R R A A G"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus", "authors": [{"first": "R", "middle": [], "last": "Xu", "suffix": ""}], "year": 2010, "venue": "Science", "volume": "328", "issn": "", "pages": "357--360", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus", "authors": [{"first": "D", "middle": [], "last": "Kobasa", "suffix": ""}], "year": 2004, "venue": "Nature", "volume": "431", "issn": "", "pages": "703--707", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses", "authors": [{"first": "Y", "middle": [], "last": "Itoh", "suffix": ""}], "year": 2009, "venue": "Nature", "volume": "460", "issn": "", "pages": "1021--1025", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "Antigenic maps comparing the initial and additional sets of antisera. Shown in (a) are the positions of the initial set of antisera (red boxes) with lines connecting their homologous antigens (blue circles = mutant viruses; cyan circle = A/Norway/3858/2009). The positions of the viruses selected for further testing with new antisera (approximately 13% of the total number of mutant viruses) are shown as orange circles. These viruses were selected based upon their original position in the map as well as the biophysical properties of the amino acids at positions 153-156. Shown in (b)", "latex": null, "type": "figure"}, "FIGREF1": {"text": "Positions of strains by numbers of amino acid mutations. In each panel, mutant viruses (red circles) possessing a given number of amino acid mutations (a = one, b = two, c = three, d = four, or e = five mutations) are shown on an antigenic map in comparison to wild-type A/Norway/3858/2009 virus (cyan circle).", "latex": null, "type": "figure"}, "FIGREF2": {"text": "Serum HI titres of immunized mice subsequently challenged with selected escape variants. Three or four mice per group were immunized by intranasal infection with 10 1.5 PFU of A/California/04/2009 virus (a) or by vaccinating twice (with a two-week interval) with an A/California/07/2009 HA split vaccine (b", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Immune evasion in mice by HA mutant viruses identified in this study. Three or four mice per group were immunized by intranasal infection with 10 1.5 PFU of A/California/04/2009 (a), or by vaccination with an A/California/07/2009 HA split vaccine (b", "latex": null, "type": "figure"}, "FIGREF4": {"text": "Immune evasion in mice by HA mutations found in field strains. Three mice per group were immunized by intranasal infection with 10 1.5 PFU of A/California/04/2009 (a), or by vaccination with an A/California/07/2009 HA split vaccine (b). Four weeks later, serum HI titres against A/California/04/2009 were determined (Supplementary Fig. 8) and mice were challenged with 10 6 PFU of A/California/04/2009 or with A/Norway/3568/2009-based reassortant viruses possessing changes in HA at positions 153-156 detected in field strains as shown on the X-axis (see also Supplementary", "latex": null, "type": "figure"}, "TABREF2": {"text": "or the representative antigenic escape mutants shown on the X-axis (seealso Supplementary Table 18). Shown are lung virus titers on day 4 post-challenge. Dashed lines, detection limit of virus (1.7 log 10 PFU/g).", "latex": null, "type": "table"}, "TABREF3": {"text": "Table 19). On day 4 post-challenge, virus titres in mouse lungs were determined. Dashed lines, detection limit of virus (1.7 log 10 PFU/g).SupplementaryFigure 11| Serum HI titres of immunized ferrets subsequently challenged with escape variants identified in this study or found in a field strain. Three or four ferrets per group were infected by intranasal inoculation with 500 PFU of A/California/04/2009 virus.SupplementaryTable 2. HA mutations identified in antigenic escape mutants selected from clinical A(H1N1)pdm09 isolates with human convalescent sera a . PFU of virus were mixed with each of the convalescent human sera and then used to infect MDCK cells. Virus-containing culture supernatants were collected from cells incubated with the highest concentration of antiserum at which a cytopathic effect was observed. Viruses were plaque-purified in MDCK cells. The HA genes of 12 plaque-purified viruses per group were sequenced. b ND, not detected, i.e., no mutations in HA were found.Yk1205-D127E, A/Yokohama/UT-K1205T/2009 possessing a D127E mutation. f Yk1205-K163E, A/Yokohama/UT-K1205T/2009 possessing a K163E mutation. g HI titres to homologous viruses are indicated in boldface. h -, not tested. NATURE MICROBIOLOGY | www.nature.com/naturemicrobiology Supplementary Table 4. Diversity of a mutant A/Norway/3858/2009 HA cDNA plasmid library a .", "latex": null, "type": "table"}, "TABREF4": {"text": "Libraries possessing random mutations at one, two, or four amino acid positions of A/Norway/3858/2009 HA a . Nomenclature example: Nr3858-N125D, A/Norway/3858/2009 possessing a N125D mutation. b WT Nr3858, wild-type A/Norway/3858/2009. Supplementary Table 12. Diversity of an A/Norway/3858/2009 HA plasmid library possessing random mutations at amino acid positions 153-156 a .", "latex": null, "type": "table"}, "TABREF5": {"text": "GCC Mutagenesis targeting amino acid positions 153-156 of A/Norway/3858/2009 HA was carried out as described in the Methods section. Thirty-four cDNA clones were sequenced to confirm the diversity of the library. b Nucleotide sequences of wild-type A/Norway/3858/2009 HA gene are shown in boldface.", "latex": null, "type": "table"}, "TABREF6": {"text": "Virus strains and HA mutants used to challenge immunized mice a . C20 Nr3858-D127E+K153A+K154L+G155N+N156K In vitro and In vivo C34 Nr3858-D127E+K153Q+K154N+G155S+N156G In vitro and In vivo C36 Nr3858-D127E+K153S+K154L+G155R+N156G In vitro and In vivo Nr3858-D127E+K153S+K154L+G155K+N156G, A/Norway/3858/2009 possessing the D127E, K153S, K154L, G155K, and N156G mutations in HA. b NA, not applicable.In vitro selection with human antiserum A163. d In vivo selection in immunized mice.", "latex": null, "type": "table"}, "TABREF7": {"text": "Table 1. Human A(H1N1)pdm09 sera used in this study.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Serum </td><td>MN </td><td>\u00a0</td><td>Date of collection</td><td>\u00a0</td><td>\u00a0</td></tr><tr><td>ID </td><td>titrec </td><td>Donor age (years) </td><td>\u00a0</td><td>Screens of wild-\ntype virusesd </td><td>Screens of virus librariese </td></tr><tr><td>C26a </td><td>512 </td><td>11 </td><td>November 21, 2009 </td><td>+ </td><td>\u2212 </td></tr><tr><td>C42a </td><td>512 </td><td>8 </td><td>November 21, 2009 </td><td>+ </td><td>\u2212 </td></tr><tr><td>C61a </td><td>512 </td><td>9 </td><td>November 21, 2009 </td><td>+ </td><td>\u2212 </td></tr><tr><td>C32a </td><td>256 </td><td>11 </td><td>November 21, 2009 </td><td>\u2212 </td><td>+ </td></tr><tr><td>C53a </td><td>256 </td><td>12 </td><td>November 21, 2009 </td><td>\u2212 </td><td>+ </td></tr><tr><td>C59a </td><td>256 </td><td>9 </td><td>November 21, 2009 </td><td>+ </td><td>+ </td></tr><tr><td>C82a </td><td>512 </td><td>10 </td><td>January 30, 2010 </td><td>+ </td><td>+ </td></tr><tr><td>C83a </td><td>512 </td><td>11 </td><td>January 30, 2010 </td><td>+ </td><td>+ </td></tr><tr><td>C84a </td><td>256 </td><td>9 </td><td>January 30, 2010 </td><td>+ </td><td>+ </td></tr><tr><td>C86a </td><td>512 </td><td>8 </td><td>January 30, 2010 </td><td>\u2212 </td><td>+ </td></tr><tr><td>C87a </td><td>256 </td><td>14 </td><td>January 30, 2010 </td><td>+ </td><td>+ </td></tr><tr><td>C89a </td><td>1024 </td><td>9 </td><td>January 30, 2010 </td><td>\u2212 </td><td>+ </td></tr><tr><td>C91a </td><td>512 </td><td>9 </td><td>January 30, 2010 </td><td>\u2212 </td><td>+ </td></tr><tr><td>C96a </td><td>256 </td><td>10 </td><td>January 30, 2010 </td><td>\u2212 </td><td>+ </td></tr><tr><td>C101a </td><td>256 </td><td>13 </td><td>January 30, 2010 </td><td>\u2212 </td><td>+ </td></tr><tr><td>C103a </td><td>256 </td><td>8 </td><td>January 30, 2010 </td><td>\u2212 </td><td>+ </td></tr><tr><td>A114a </td><td>256 </td><td>46 </td><td>January 30, 2010 </td><td>\u2212 </td><td>+ </td></tr><tr><td>A163b </td><td>1024 </td><td>39 </td><td>March 25, 2010 </td><td>\u2212 </td><td>+ </td></tr></table></body></html>"}, "TABREF8": {"text": "Table 2. HA mutations identified in antigenic escape mutants selected from clinical A(H1N1)pdm09 isolates with human convalescent sera a .", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Serum ID </td><td>HA mutation(s) found in plaque-purified viruses (number of clones with mutations/number of clones examined) using:  </td></tr><tr><td>A/Norway/3206-3/2009 </td><td>A/Yokohama/UT-K1205T/2009 </td></tr><tr><td>C26 </td><td>ND (0/12 clones)b </td><td>-c </td></tr><tr><td>C42 </td><td>K153E+N239K (12/12 clones) </td><td>- </td></tr><tr><td>C61 </td><td>K153E+N239K (12/12 clones) </td><td>- </td></tr><tr><td>C59 </td><td>K153E+N239K (12/12 clones) </td><td>D127E (12/12 clones) </td></tr><tr><td>C82 </td><td>ND (0/12 clones) </td><td>D127E (10/12 clones) </td></tr><tr><td>C83 </td><td>K153E+N239K (10/12 clones) </td><td>D127E (6/12 clones) </td></tr><tr><td>C84 </td><td>ND (0/12 clones) </td><td>ND (0/12 clones) </td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>D127E (4/12 clones) </td></tr><tr><td>C87 </td><td>K153E+N239K (6/12 clones) </td><td>\u00a0</td></tr><tr><td>\u00a0</td><td>\u00a0</td><td>K163E (8/12 clones) </td></tr></table></body></html>"}, "TABREF9": {"text": "Table 3. Antigenic characterization of escape mutants from A(H1N1)pdm09 viruses by HI assay a .", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Virus </td><td>HI titre with antisera raised against: </td></tr><tr><td>WT Nr3206 </td><td>Nr3206- K153E+N239K </td><td>WT Yk1205 </td></tr><tr><td>WT Nr3206b </td><td>1280g </td><td>320 </td><td>- </td></tr><tr><td>Nr3206-K153E+N239Kc </td><td>160 </td><td>320/640 </td><td>- </td></tr><tr><td>WT Yk1205d </td><td>-h </td><td>- </td><td>1280 </td></tr><tr><td>Yk1205-D127Ee </td><td>- </td><td>- </td><td>320/640 </td></tr><tr><td>Yk1205-K163Ef </td><td>- </td><td>- </td><td>640 </td></tr></table></body></html>"}, "TABREF10": {"text": "Table 4. Diversity of a mutant A/Norway/3858/2009 HA cDNA plasmid library a .", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>Clone number (%) </td></tr><tr><td>Total clones sequenced </td><td>24 </td></tr><tr><td>Wild-type clones </td><td>2 (8%) </td></tr><tr><td>Non-functional mutant clonesb </td><td>6 (25%) </td></tr><tr><td>1 amino acid change </td><td>5 (31%) </td></tr><tr><td>2 amino acid changes </td><td>6 (38%) </td></tr><tr><td>3 amino acid changes </td><td>3 (19%) </td></tr><tr><td>Functional mutant 4 amino acid changes </td><td>1 (6%) </td></tr><tr><td>clones 5 amino acid changes </td><td>1 (6%) </td></tr><tr><td>Total number of clones with change(s) </td><td>amino acid 16 (67%) </td></tr></table></body></html>"}, "TABREF11": {"text": "Table 6. Libraries possessing random mutations at one, two, or four amino acid positions of A/Norway/3858/2009 HA a .", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Mutation target (HA amino acid position) </td><td>E. coli transformation efficiency (CFUb) </td><td>Transfectant virus titre (PFU/ml) </td><td>Stock virus titre (PFU/ml) </td></tr><tr><td>125 </td><td>2.7\u00d7106 </td><td>1.1\u00d7107 </td><td>2.0\u00d7108 </td></tr><tr><td>127 </td><td>2.9\u00d7105 </td><td>5.0\u00d7104 </td><td>1.4\u00d7108 </td></tr><tr><td>129 </td><td>7.9\u00d7105 </td><td>9.0\u00d7106 </td><td>5.0\u00d7107 </td></tr><tr><td>141 </td><td>4.0\u00d7105 </td><td>1.0\u00d7106 </td><td>1.3\u00d7108 </td></tr><tr><td>142 </td><td>1.5\u00d7105 </td><td>4.4\u00d7106 </td><td>7.0\u00d7107 </td></tr><tr><td>152 </td><td>2.6\u00d7106 </td><td>2.5\u00d7105 </td><td>1.1\u00d7108 </td></tr><tr><td>153 </td><td>8.8\u00d7105 </td><td>3.3\u00d7107 </td><td>5.5\u00d7107 </td></tr><tr><td>154 </td><td>3.4\u00d7105 </td><td>7.0\u00d7107 </td><td>1.0\u00d7108 </td></tr><tr><td>155 </td><td>1.4\u00d7106 </td><td>1.2\u00d7107 </td><td>1.8\u00d7108 </td></tr><tr><td>156 </td><td>9.3\u00d7105 </td><td>1.1\u00d7107 </td><td>1.5\u00d7108 </td></tr><tr><td>163 </td><td>1.9\u00d7105 </td><td>1.3\u00d7107 </td><td>3.0\u00d7107 </td></tr><tr><td>183 </td><td>6.8\u00d7104 </td><td>5.1\u00d7105 </td><td>6.0\u00d7107 </td></tr><tr><td>186 </td><td>7.4\u00d7105 </td><td>1.7\u00d7106 </td><td>1.1\u00d7108 </td></tr><tr><td>187 </td><td>3.4\u00d7105 </td><td>3.4\u00d7104 </td><td>2.0\u00d7108 </td></tr><tr><td>190 </td><td>6.2\u00d7105 </td><td>1.5\u00d7106 </td><td>1.4\u00d7108 </td></tr><tr><td>153+154 </td><td>7.8\u00d7105 </td><td>5.0\u00d7106 </td><td>9.0\u00d7107 </td></tr><tr><td>153+155 </td><td>7.5\u00d7105 </td><td>2.1\u00d7107 </td><td>1.2\u00d7108 </td></tr><tr><td>153+156 </td><td>6.6\u00d7105 </td><td>1.7\u00d7107 </td><td>4.3\u00d7108 </td></tr><tr><td>154+155 </td><td>7.2\u00d7105 </td><td>2.4\u00d7107 </td><td>2.2\u00d7108 </td></tr><tr><td>154+156 </td><td>5.6\u00d7105 </td><td>2.7\u00d7107 </td><td>7.5\u00d7107 </td></tr><tr><td>155+156 </td><td>1.1\u00d7106 </td><td>1.0\u00d7107 </td><td>2.7\u00d7108 </td></tr><tr><td>153+154+155+156 </td><td>1.6\u00d7106 </td><td>6.8\u00d7107 </td><td>3.1\u00d7108 </td></tr><tr><td>D127E 153+154+155+156 </td><td>7.5\u00d7106 </td><td>4.9\u00d7107 </td><td>4.3\u00d7108 </td></tr></table></body></html>"}, "TABREF12": {"text": "Table 7. Antisera used to screen A/Norway/3858/2009 HA libraries possessing random mutations at one, two, or four amino acid positions.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Targeted site in HA (amino acid position) </td><td>Antisera used for screening (raised in ferrets unless noted otherwise) </td></tr><tr><td>125 </td><td>Nr3858-N125Da </td></tr><tr><td>127 </td><td>Nr3858-D127E </td></tr><tr><td>129 </td><td>Nr3858-N129D </td></tr><tr><td>153 </td><td>Nr3858-K153E </td></tr><tr><td>154 </td><td>Nr3858-K154N </td></tr><tr><td>155 </td><td>Nr3858-G155E </td></tr><tr><td>156 </td><td>Nr3858-N156D </td></tr><tr><td>163 </td><td>Nr3858-K163E </td></tr><tr><td>183 </td><td>Nr3858-S183P </td></tr><tr><td>141 </td><td>WT Nr3858b </td></tr><tr><td>142 </td><td>WT Nr3858 </td></tr><tr><td>152 </td><td>WT Nr3858 </td></tr><tr><td>186 </td><td>WT Nr3858 </td></tr><tr><td>187 </td><td>WT Nr3858 </td></tr><tr><td>190 </td><td>WT Nr3858 </td></tr><tr><td>153+154 </td><td>Nr3858-K153E and Nr3858-K154N </td></tr><tr><td>153+155 </td><td>Nr3858-K153E and Nr3858-G155E </td></tr><tr><td>153+156 </td><td>Nr3858-K153E and Nr3858-N156D </td></tr><tr><td>154+155 </td><td>Nr3858-K154N and Nr3858-G155E </td></tr><tr><td>154+156 </td><td>Nr3858-K154N and Nr3858-N156D </td></tr><tr><td>155+156 </td><td>Nr3858-G155E and Nr3858-N156D </td></tr><tr><td>153+154+155+156 D127E 153+154+155+156 </td><td>Human antiserum A163 Human antiserum A163 </td></tr></table></body></html>"}, "TABREF13": {"text": "Table 12. Diversity of an A/Norway/3858/2009 HA plasmid library possessing random mutations at amino acid positions 153-156 a .", "latex": null, "type": "table", "html": "<html><body><table><tr><td>153 </td><td>Codon for amino 154 </td><td>acid at position: 155 </td><td>156 </td></tr><tr><td>AAAb </td><td>AAA </td><td>GGA </td><td>AAT </td></tr><tr><td>GCT </td><td>ATG </td><td>AAC </td><td>CTG </td></tr><tr><td>AAC </td><td>TAG* </td><td>GAT </td><td>TGC </td></tr><tr><td>CGA </td><td>TTT </td><td>GGA </td><td>AGA </td></tr><tr><td>ACA </td><td>GGG </td><td>AAA </td><td>AGT </td></tr><tr><td>GGT </td><td>TCC </td><td>ATC </td><td>AGG </td></tr><tr><td>TTC </td><td>TGT </td><td>TTT </td><td>AGG </td></tr><tr><td>TCC </td><td>TCC </td><td>TCC </td><td>CTA </td></tr><tr><td>TGT </td><td>GCT </td><td>GTA </td><td>GAC </td></tr><tr><td>AAA </td><td>CAC </td><td>TCG </td><td>AAT </td></tr><tr><td>TGT </td><td>CAT </td><td>CGT </td><td>TCC </td></tr><tr><td>TGA*c </td><td>AAA </td><td>TGA* </td><td>GAT </td></tr><tr><td>GGT </td><td>AGG </td><td>GTG </td><td>ATA </td></tr><tr><td>TCC </td><td>GGT </td><td>ATT </td><td>GAA </td></tr><tr><td>TTG </td><td>CCT </td><td>TTT </td><td>TTT </td></tr><tr><td>AAA </td><td>ATT </td><td>ATT </td><td>CGC </td></tr><tr><td>ACG </td><td>ATC </td><td>TCG </td><td>GCA </td></tr><tr><td>TCT </td><td>TCG </td><td>GGG </td><td>AGT </td></tr><tr><td>GTT </td><td>TGA* </td><td>TGT </td><td>GAC </td></tr><tr><td>TCA </td><td>TCG </td><td>GAT </td><td>TGT </td></tr><tr><td>GGT </td><td>TCA </td><td>TAA* </td><td>GAC </td></tr><tr><td>GCT </td><td>AGG </td><td>CAA </td><td>TTC </td></tr><tr><td>TTT </td><td>GCA </td><td>AGA </td><td>TAA* </td></tr><tr><td>TTC </td><td>GTT </td><td>TAC </td><td>GGG </td></tr><tr><td>CCC </td><td>TGG </td><td>GCG </td><td>GCG </td></tr><tr><td>AAG </td><td>GAC </td><td>TAA* </td><td>GAG </td></tr><tr><td>TTT </td><td>GTA </td><td>CGA </td><td>ACC </td></tr><tr><td>CTG </td><td>GGA </td><td>TTT </td><td>TGA* </td></tr><tr><td>ACG </td><td>GGT </td><td>CCA </td><td>AAA </td></tr><tr><td>AAC </td><td>AGC </td><td>GTA </td><td>CTA </td></tr><tr><td>TTT </td><td>GAC </td><td>CCT </td><td>ACT </td></tr><tr><td>GGC </td><td>TCC </td><td>TGG </td><td>TCG </td></tr><tr><td>AAA </td><td>AGA </td><td>GAG </td><td>TCG </td></tr><tr><td>AGC </td><td>AAA </td><td>GTG </td><td>TGC </td></tr><tr><td>GAA </td><td>AGG </td><td>CCA </td><td>GCC </td></tr></table></body></html>"}, "TABREF14": {"text": "Table 13. Diversity of an A/Norway/3858/2009 HA plasmid library possessing the D127E mutation and random mutations at amino acid positions 153- 156 a . Codon for amino acid at position:", "latex": null, "type": "table", "html": "<html><body><table><tr><td>153 </td><td>154 </td><td>155 </td><td>156 </td></tr><tr><td>AAAb </td><td>AAA </td><td>GGA </td><td>AAT </td></tr><tr><td>ACA </td><td>AGC </td><td>AGC </td><td>TTC </td></tr><tr><td>GGA </td><td>CTG </td><td>GAT </td><td>ATC </td></tr><tr><td>AGG </td><td>GTC </td><td>TAG* </td><td>GTA </td></tr><tr><td>ATT </td><td>ATA </td><td>GGT </td><td>TTA </td></tr><tr><td>CAC </td><td>ACG </td><td>TTA </td><td>CAG </td></tr><tr><td>TGA*c </td><td>CTA </td><td>GGC </td><td>CCG </td></tr><tr><td>AAA </td><td>GGT </td><td>TCG </td><td>CCC </td></tr><tr><td>GGT </td><td>AGT </td><td>GAG </td><td>GGT </td></tr><tr><td>AAA </td><td>AAA </td><td>GGA </td><td>AAT </td></tr><tr><td>GTA </td><td>GAA </td><td>TGA* </td><td>TGC </td></tr><tr><td>GGA </td><td>ACC </td><td>AAG </td><td>TTT </td></tr><tr><td>AAT </td><td>GTG </td><td>TGT </td><td>GGC </td></tr><tr><td>GCT </td><td>TGC </td><td>TTT </td><td>CCA </td></tr><tr><td>GGT </td><td>CAC </td><td>AGT </td><td>AGT </td></tr><tr><td>TTG </td><td>CCA </td><td>GTC </td><td>AGC </td></tr><tr><td>TAA* </td><td>CGG </td><td>ATG </td><td>AGC </td></tr><tr><td>TTC </td><td>TTA </td><td>GGG </td><td>TGT </td></tr><tr><td>GAA </td><td>GGG </td><td>CTG </td><td>CAT </td></tr><tr><td>TTC </td><td>TAT </td><td>CAG </td><td>TCC </td></tr><tr><td>CAG </td><td>GAC </td><td>AAT </td><td>GCT </td></tr><tr><td>AGT </td><td>GCG </td><td>ACC </td><td>GGA </td></tr><tr><td>TCG </td><td>TCA </td><td>ATA </td><td>ACC </td></tr><tr><td>GTA </td><td>TCC </td><td>TTG </td><td>GAG </td></tr><tr><td>TCA </td><td>GTT </td><td>ATC </td><td>CGG </td></tr><tr><td>CAA </td><td>CGT </td><td>CTG </td><td>CGC </td></tr><tr><td>GTG </td><td>TGT </td><td>TCG </td><td>TGG </td></tr><tr><td>TGG </td><td>TCT </td><td>GAA </td><td>AAA </td></tr></table></body></html>"}, "TABREF15": {"text": "Table 14. Selection of antigenic escape mutants in mice.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Mouse ID </td><td>Mouse strain </td><td>HI titre of mouse seruma </td><td>Challenge virus </td><td>Virus titre in lungsc (PFU/g) </td></tr><tr><td>1 </td><td>\u00a0</td><td>80 </td><td>\u00a0</td><td>&lt;50 </td></tr><tr><td>2 </td><td>\u00a0</td><td>80 </td><td>WT CA04b </td><td>&lt;50 </td></tr><tr><td>3 </td><td>BALB/c </td><td>&lt;10 </td><td>\u00a0</td><td>7.39\u00d7106 </td></tr><tr><td>4 </td><td>\u00a0</td><td>&lt;10 </td><td>\u00a0</td><td>1.18\u00d7107 </td></tr><tr><td>5 </td><td>\u00a0</td><td>80 </td><td>Nr3858 with 5 </td><td>2.42\u00d7102 </td></tr><tr><td>6 </td><td>\u00a0</td><td>&lt;10 </td><td>mutationsd </td><td>8.57\u00d7106 </td></tr><tr><td>7 </td><td>\u00a0</td><td>40 </td><td>\u00a0</td><td>&lt;50 </td></tr><tr><td>8 </td><td>\u00a0</td><td>80/160 </td><td>WT CA04 </td><td>&lt;50 </td></tr><tr><td>9 </td><td>C57BL6/J </td><td>80 </td><td>\u00a0</td><td>&lt;50 </td></tr><tr><td>10 </td><td>\u00a0</td><td>80 </td><td>\u00a0</td><td>1.05\u00d7103 </td></tr><tr><td>11 </td><td>\u00a0</td><td>80/160 </td><td>Nr3858 with 5 </td><td>&lt;50 </td></tr><tr><td>\u00a0</td><td>12 </td><td>80/160 </td><td>mutations </td><td>&lt;50 </td></tr></table></body></html>"}, "TABREF16": {"text": "Table 16. Virus strains and HA mutants used to raise ferret antisera for antigenic cartography.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Virus type </td><td>Virus strain or HA mutant </td></tr><tr><td>A/California/04/2009 </td></tr><tr><td>\u00a0</td><td>A/Norway/3568/2009 </td></tr><tr><td>\u00a0</td><td>A/Norway/3206-3/2009 </td></tr><tr><td>\u00a0</td><td>A/Norway/3206-3/2009-K153E+N239Ka </td></tr><tr><td>\u00a0</td><td>A/Yokohama/UT-K1205T/2009 </td></tr><tr><td>\u00a0</td><td>A/Yokohama/UT-K1205T/2009-K163E A/Norway/3858/2009 </td></tr><tr><td>\u00a0</td><td>A/Norway/3858/2009-N125D </td></tr><tr><td>A(H1N1)pdm09 </td><td>A/Norway/3858/2009-D127E </td></tr><tr><td>A/Norway/3858/2009-N129D </td></tr><tr><td>A/Norway/3858/2009-K153E </td></tr><tr><td>\u00a0</td><td>A/Norway/3858/2009-K154N A/Norway/3858/2009-G155E </td></tr><tr><td>\u00a0</td><td>A/Norway/3858/2009-N156D </td></tr><tr><td>\u00a0</td><td>A/Norway/3858/2009-K163E </td></tr><tr><td>\u00a0</td><td>A/Norway/3858/2009-S183P </td></tr><tr><td>\u00a0</td><td>A/Norway/3858/2009-K154G+N156V </td></tr><tr><td>\u00a0</td><td>A/Norway/3858/2009-K153S+K154L+G155R+N156S </td></tr><tr><td>\u00a0</td><td>A/Norway/3858/2009-D127E+K153A+K154L+G155R+N156G </td></tr><tr><td>\u00a0</td><td>A/swine/Iowa/15/1930 </td></tr><tr><td>Seasonal human and swine </td><td>A/New Jersey/8/1976 </td></tr><tr><td>A/Wisconsin/10/1998 </td></tr><tr><td>H1N1 viruses </td><td>A/Wisconsin/87/2005 </td></tr><tr><td>A/Ohio/01/2007 </td></tr><tr><td>\u00a0</td><td>A/Texas/14/2008 </td></tr></table></body></html>"}, "TABREF17": {"text": "Table 17. A(H1N1)pdm09 HA mutants used to raise additional ferret antisera to potentially improve mutant virus resolution by antigenic cartography.", "latex": null, "type": "table", "html": "<html><body><table><tr><td>A(H1N1)pdm09 HA mutant </td><td>Property </td></tr><tr><td>A/Norway/3858/2009-N125G </td><td>Antigenically close to wild-type viruses </td></tr><tr><td>A/Norway/3858/2009-D127S </td><td>Amino acid close to 153/156 loop in structure of HA </td></tr><tr><td>A/Norway/3858/2009-K153H+N156H </td><td>All large aromatic amino acids </td></tr><tr><td>A/Norway/3858/2009-K154N+S183P </td><td>Antigenically in intermediate cluster </td></tr><tr><td>A/Norway/3858/2009-D127E+K153S+N156T </td><td>All negative or polar amino acids </td></tr><tr><td>A/Norway/3858/2009-K153A+K154A+N156G </td><td>All small, hydrophobic amino acids </td></tr><tr><td>A/Norway/3858/2009-K153Q+K154Q+G155R </td><td>All positive amino acids </td></tr><tr><td>A/Norway/3858/2009-\n</td><td>Virus most distant from others antigenically </td></tr><tr><td>K153S+K154G+G155Y+N156G* </td><td>\u00a0</td></tr><tr><td>A/Norway/3858/2009-\n</td><td>Mixed size and charge of amino </td></tr><tr><td>D127E+K153R+K154G+G155H+N156S </td><td>acids </td></tr><tr><td>A/Norway/3858/2009- </td><td>All large amino acids </td></tr><tr><td>\u00a0</td><td>D127E+K153R+K154R+G155E+N156H </td></tr></table></body></html>"}, "TABREF18": {"text": "Table 18. Virus strains and HA mutants used to challenge immunized mice a .", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Virus ID </td><td>Virus strain or HA mutant </td><td>Method by which the HA mutant was selected </td></tr><tr><td>CA04 </td><td>A/California/04/2009 </td><td>NAb </td></tr><tr><td>Nr3858 </td><td>A/Norway/3858/2009 </td><td>NA </td></tr><tr><td>C1 </td><td>Nr3858-D127E+K153S+K154L+G155K+N156Ga </td><td>In vitroc and In vivod </td></tr><tr><td>3-2/3 </td><td>Nr3858-D127E+K153A+K154L+G155R+N156G </td><td>In vivo </td></tr><tr><td>C20 </td><td>Nr3858-D127E+K153A+K154L+G155N+N156K </td><td>In vitro and In vivo </td></tr><tr><td>C34 </td><td>Nr3858-D127E+K153Q+K154N+G155S+N156G </td><td>In vitro and In vivo </td></tr><tr><td>C36 </td><td>Nr3858-D127E+K153S+K154L+G155R+N156G </td><td>In vitro and In vivo </td></tr><tr><td>C47 </td><td>Nr3858-D127E+K153G+K154I+G155N+N156R </td><td>In vitro </td></tr><tr><td>C53 </td><td>Nr3858-D127E+K153R+K154L+G155S+N156G </td><td>In vitro </td></tr><tr><td>16-1/3 </td><td>Nr3858-D127E+K153R+K154R+G155E+N156H </td><td>In vivo </td></tr><tr><td>16-1/4 </td><td>Nr3858-D127E+K153A+K154L+G155Q+N156K </td><td>In vivo </td></tr><tr><td>16-1/8 </td><td>Nr3858-D127E+K153A+G155H+N156G </td><td>In vivo </td></tr><tr><td>16-1/11 </td><td>Nr3858-D127E+K153G+K154L+G155R+N156G </td><td>In vivo </td></tr><tr><td>16-1/27 </td><td>Nr3858-D127E+K153A+K154N+G155R+N156G </td><td>In vivo </td></tr><tr><td>029/13 </td><td>Nr3858-K153S+K154G+G155Y+N156G </td><td>In vitro </td></tr></table></body></html>"}, "TABREF19": {"text": "Table 19. Reassortant viruses used to challenge immunized mice a .", "latex": null, "type": "table", "html": "<html><body><table><tr><td>Virus ID </td><td>HA mutation compared to A/Norway/3858/2009 </td><td>Origin of HA and NA genesb </td></tr><tr><td>153 </td><td>K153E </td><td>A/New York/4557/2009 </td></tr><tr><td>154 </td><td>K154E </td><td>A/New York/4459/2009 </td></tr><tr><td>155-A </td><td>G155E </td><td>A/Bangkok/INS425/2010 </td></tr><tr><td>155-B </td><td>G155E </td><td>A/Jiangsu/1/2009 </td></tr><tr><td>156-A </td><td>N156S </td><td>A/Qingdao/1610/2009c </td></tr><tr><td>156-B </td><td>N156T </td><td>A/Wisconsin/629/D00223/2009 </td></tr><tr><td>153+155 </td><td>K153E+G155E </td><td>A/Miyazaki/40/2011d,e </td></tr><tr><td>154+155 </td><td>K154Q+G155E </td><td>A/Okinawa/41/2010d,e </td></tr><tr><td>155+156-A </td><td>G155E+N156S </td><td>A/Cameroon/LEID/01/11/1398/2010e </td></tr><tr><td>155+156-B </td><td>G155E+N156K </td><td>A/Townsville/56/2010 </td></tr></table></body></html>"}, "TABREF20": {"text": "Table 22. Human sera used in A/Texas/50/2012 (H3N2) escape mutant selection", "latex": null, "type": "table", "html": "<html><body><table><tr><td>\u00a0</td><td>\u00a0</td><td>HI </td><td>Donor age (years) </td><td>\u00a0</td></tr><tr><td>Serum IDa </td><td>Group No.b </td><td>titrec </td><td>\u00a0</td><td>Date of collection </td></tr><tr><td>LS 2361308A </td><td>2 </td><td>40 </td><td>31 </td><td>December 1, 2013 </td></tr><tr><td>LS 2361081A </td><td>2 </td><td>40 </td><td>33 </td><td>December 4, 2013 </td></tr><tr><td>LS 2361252A </td><td>3 </td><td>80 </td><td>46 </td><td>December 10, 2013 </td></tr><tr><td>LS 5543568A </td><td>2 </td><td>160 </td><td>37 </td><td>December 30, 2013 </td></tr><tr><td>LS 2362317A </td><td>3 </td><td>160 </td><td>53 </td><td>January 21, 2014 </td></tr><tr><td>LS 8812408A </td><td>1 </td><td>160 </td><td>25 </td><td>January 23, 2014 </td></tr><tr><td>LS 8812407A </td><td>1 </td><td>160 </td><td>29 </td><td>January 23, 2014 </td></tr><tr><td>LS 8812404A </td><td>2 </td><td>160 </td><td>30 </td><td>January 23, 2014 </td></tr><tr><td>LS 8812400A </td><td>1 </td><td>80 </td><td>23 </td><td>January 23, 2014 </td></tr><tr><td>LS 5543871A </td><td>3 </td><td>80 </td><td>59 </td><td>January 23, 2014 </td></tr></table></body></html>"}}, "back_matter": [{"text": " AAA  GGA  AAT  ACA  AGC  AGC  TTC  GGA  CTG  GAT  ATC  AGG  GTC  TAG*  GTA  ATT  ATA  GGT  TTA  CAC  ACG  TTA  CAG  TGA* c  CTA  GGC  CCG  AAA  GGT  TCG  CCC  GGT  AGT  GAG  GGT  AAA  AAA  GGA  AAT  GTA  GAA  TGA*  TGC  GGA  ACC  AAG  TTT  AAT  GTG  TGT  GGC  GCT  TGC  TTT  CCA  GGT  CAC  AGT  AGT  TTG  CCA  GTC  AGC  TAA*  CGG  ATG  AGC  TTC  TTA  GGG  TGT  GAA  GGG  CTG  CAT  TTC  TAT  CAG  TCC  CAG  GAC  AAT  GCT  AGT  GCG  ACC  GGA  TCG  TCA  ATA  ACC  GTA  TCC  TTG  GAG  TCA  GTT  ATC  CGG  CAA  CGT  CTG  CGC  GTG  TGT  TCG  TGG  TGG  TCT  GAA Haemagglutination inhibition (HI) titres were determined using standard HI assays with 0.75% guinea pig red blood cells and the amount of A/Texas/50/2012 (H3N2) virus equivalent to 8 haemagglutinating units.", "cite_spans": [], "ref_spans": [{"start": 1, "end": 555, "text": "AAA  GGA  AAT  ACA  AGC  AGC  TTC  GGA  CTG  GAT  ATC  AGG  GTC  TAG*  GTA  ATT  ATA  GGT  TTA  CAC  ACG  TTA  CAG  TGA* c  CTA  GGC  CCG  AAA  GGT  TCG  CCC  GGT  AGT  GAG  GGT  AAA  AAA  GGA  AAT  GTA  GAA  TGA*  TGC  GGA  ACC  AAG  TTT  AAT  GTG  TGT  GGC  GCT  TGC  TTT  CCA  GGT  CAC  AGT  AGT  TTG  CCA  GTC  AGC  TAA*  CGG  ATG  AGC  TTC  TTA  GGG  TGT  GAA  GGG  CTG  CAT  TTC  TAT  CAG  TCC  CAG  GAC  AAT  GCT  AGT  GCG  ACC  GGA  TCG  TCA  ATA  ACC  GTA  TCC  TTG  GAG  TCA  GTT  ATC  CGG  CAA  CGT  CTG  CGC  GTG  TGT  TCG  TGG  TGG  TCT  GAA", "ref_id": null}], "section": "SUPPLEMENTARY INFORMATION Supplementary"}]}